From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease

array:25 ["pii" => "S217358081300182X" "issn" => "21735808" "doi" => "10.1016/j.nrleng.2013.12.004" "estado" => "S300" "fechaPublicacion" => "2014-03-01" "aid" => "480" "copyright" => "Sociedad Española de Neurología" "copyrightAnyo" => "2012" "documento" => "article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Neurologia. 2014;29:86-93" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2340 "formatos" => array:3 [ "EPUB" => 43 "HTML" => 1714 "PDF" => 583 ] ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0213485313000571" "issn" => "02134853" "doi" => "10.1016/j.nrl.2013.02.012" "estado" => "S300" "fechaPublicacion" => "2014-03-01" "aid" => "480" "copyright" => "Sociedad Española de Neurología" "documento" => "article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Neurologia. 2014;29:86-93" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4478 "formatos" => array:3 [ "EPUB" => 47 "HTML" => 3614 "PDF" => 817 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "Original" "titulo" => "Experiencia de uso y satisfacción con rivastigmina transdérmica en cuidadores de pacientes con enfermedad de Alzheimer de leve a moderada previamente tratados con rivastigmina oral a dosis altas" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "86" "paginaFinal" => "93" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figura 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1014 "Ancho" => 2392 "Tamanyo" => 133749 ] ] "descripcion" => array:1 [ "es" => "Impresión Clínica Global de Cambio (ICG-C) en el estado de los pacientes, notificada por cuidadores e investigadores y respecto al tratamiento anterior." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Reñé, J. Ricart, B. Hernández" "autores" => array:4 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Reñé" ] 1 => array:2 [ "nombre" => "J." "apellidos" => "Ricart" ] 2 => array:2 [ "nombre" => "B." "apellidos" => "Hernández" ] 3 => array:1 [ "colaborador" => "en representación de los investigadores del Estudio Experience" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S217358081300182X" "doi" => "10.1016/j.nrleng.2013.12.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217358081300182X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485313000571?idApp=UINPBA00004N" "url" => "/02134853/0000002900000002/v1_201403030022/S0213485313000571/v1_201403030022/es/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S2173580814000108" "issn" => "21735808" "doi" => "10.1016/j.nrleng.2013.02.002" "estado" => "S300" "fechaPublicacion" => "2014-03-01" "aid" => "481" "copyright" => "Sociedad Española de Neurología" "documento" => "article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Neurologia. 2014;29:94-101" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2770 "formatos" => array:3 [ "EPUB" => 51 "HTML" => 2126 "PDF" => 593 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Original article" "titulo" => "Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "94" "paginaFinal" => "101" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Estudio postautorización de la eslicarbazepina en el tratamiento de epilepsias farmacorresistentes: resultados preliminares" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1459 "Ancho" => 1653 "Tamanyo" => 113260 ] ] "descripcion" => array:1 [ "en" => "Patients with adverse effects (AE) during ESL treatment (n=61), specifying which AEs were not transient (some patients experienced more than one type of AE)." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Massot, R. Vivanco, A. Principe, J. Roquer, R. Rocamora" "autores" => array:5 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Massot" ] 1 => array:2 [ "nombre" => "R." "apellidos" => "Vivanco" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "Principe" ] 3 => array:2 [ "nombre" => "J." "apellidos" => "Roquer" ] 4 => array:2 [ "nombre" => "R." "apellidos" => "Rocamora" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0213485313000583" "doi" => "10.1016/j.nrl.2013.02.013" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485313000583?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580814000108?idApp=UINPBA00004N" "url" => "/21735808/0000002900000002/v1_201403090041/S2173580814000108/v1_201403090041/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S2173580814000091" "issn" => "21735808" "doi" => "10.1016/j.nrleng.2013.02.001" "estado" => "S300" "fechaPublicacion" => "2014-03-01" "aid" => "478" "copyright" => "Sociedad Española de Neurología" "documento" => "article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Neurologia. 2014;29:76-85" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 3320 "formatos" => array:3 [ "EPUB" => 65 "HTML" => 2679 "PDF" => 576 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Original article" "titulo" => "Bradycardia in frontotemporal dementia" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "76" "paginaFinal" => "85" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Bradicardia en la demencia frontotemporal" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1125 "Ancho" => 1500 "Tamanyo" => 257579 ] ] "descripcion" => array:1 [ "en" => "Brain MRI in a patient with FTD and bradycardia. Female patient aged 65 with a 3-year history of FTD-behavioural variant. Readings of 39 and 51bpm in 2 consecutive consultations. Coronal inversion recovery sequences. Note the marked atrophy of the right temporal lobe. In the lower section, the dotted area marks the amygdala and the striped area marks the insular cortex." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Robles Bayón, F. Gude Sampedro, J.M. Torregrosa Quesada" "autores" => array:3 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Robles Bayón" ] 1 => array:2 [ "nombre" => "F." "apellidos" => "Gude Sampedro" ] 2 => array:2 [ "nombre" => "J.M." "apellidos" => "Torregrosa Quesada" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0213485313000558" "doi" => "10.1016/j.nrl.2013.02.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485313000558?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580814000091?idApp=UINPBA00004N" "url" => "/21735808/0000002900000002/v1_201403090041/S2173580814000091/v1_201403090041/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "Original article" "titulo" => "From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "86" "paginaFinal" => "93" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "R. Reñé, J. Ricart, B. Hernández" "autores" => array:4 [ 0 => array:4 [ "nombre" => "R." "apellidos" => "Reñé" "email" => array:1 [ 0 => "udtd@bellvitgehospital.cat" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "¿" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "J." "apellidos" => "Ricart" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "B." "apellidos" => "Hernández" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 3 => array:1 [ "colaborador" => "representing researchers in the Experience study" ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Unidad de Diagnóstico y Tratamiento de las Demencias, Servicio de Neurología, Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Departamento Médico, Novartis Farmacéutica, S.A., Barcelona, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Experiencia de uso y satisfacción con rivastigmina transdérmica en cuidadores de pacientes con enfermedad de Alzheimer de leve a moderada previamente tratados con rivastigmina oral a dosis altas" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1340 "Ancho" => 2799 "Tamanyo" => 264981 ] ] "descripcion" => array:1 [ "en" => "Caregivers’ and researchers’ overall satisfaction with the current treatment (rivastigmine patch) for patients with AD. Items 7 and 5 from the respective ad hoc questionnaires." ] ] ] "textoCompleto" => "IntroductionTreatment for mild to moderate Alzheimer disease (AD) is based on oral acetylcholinesterase inhibitors (AChEI) such as rivastigmine, donepezil, and galantamine.<a class="elsevierStyleCrossRef" href="#bib0005">1</a> These drugs have been shown to exert a dose-dependent beneficial effect on cognitive function.<a class="elsevierStyleCrossRefs" href="#bib0010">2,3</a> However, the incidence of adverse events also increases with the dose—especially when there is no prior dose adjustment period—and with the peak plasma concentrations resulting from oral administration.<a class="elsevierStyleCrossRef" href="#bib0020">4</a> The first transdermal treatment for AD has now been approved: a rivastigmine patch<a class="elsevierStyleCrossRef" href="#bib0025">5</a> that continuously releases the drug over the 24hours after application.<a class="elsevierStyleCrossRef" href="#bib0030">6</a> Dosed at 9.5mg/day, this patch has an effect equivalent to that of higher doses of oral rivastigmine, and it is associated with fewer adverse gastrointestinal effects.<a class="elsevierStyleCrossRef" href="#bib0035">7</a> It has also been shown that patients treated with high doses of oral rivastigmine may change directly to the transdermal patch dosed at 9.5ml/day with no need for a prior adjustment period and without experiencing further adverse effects.<a class="elsevierStyleCrossRef" href="#bib0040">8</a>Treatment for patients with AD is generally managed by caregivers.<a class="elsevierStyleCrossRef" href="#bib0045">9</a> As a result, their assessment of treatment efficacy and the workload generated by the treatment may have a decisive effect on efforts to improve treatment compliance and ensure that the patient obtains the greatest benefit from the drugs prescribed.<a class="elsevierStyleCrossRef" href="#bib0050">10</a> Earlier studies have reported a better user experience, higher satisfaction, and less interference in the carer's daily activities with transdermal rivastigmine than with oral rivastigmine.<a class="elsevierStyleCrossRefs" href="#bib0055">11,12</a>The purpose of our study was to report on user experience with high doses of transdermal rivastigmine among informal caregivers of patients with mild to moderate AD. Likewise, we gathered data about caregiver satisfaction and preferences regarding the transdermal route, any improvements perceived in patients after the change from oral treatment, and treatment adherence. At the same time, we analysed user experience, satisfaction, and any perceived improvements in patients treated transdermally as reported by healthcare professionals treating patients with AD.Patients and methodsThis cross-sectional multi-centre observational study was carried out across Spain. During a 6-month period, informal caregivers were recruited consecutively during routine visits to different participating neurology, psychiatry, or geriatric care clinics. Inclusion criteria were as follows: (a) caring for a patient with mild to moderate AD (defined as a score ≥10 and <26 on the Mini-Mental State Exam [MMSE]) who was on stable treatment during ≥6 months with the highest approved dose of transdermal rivastigmine (9.5mg/day), and who previously had received high doses of oral rivastigmine (9–12mg/day); (b) having cared for the patient for at least 1 year; (c) being responsible for managing the patient's medications, and (d) being able to provide accurate information about the study variables. We excluded caregivers of patients with severe AD (MMSE<10) or dementia of other causes, paid caregivers, and those considered by researchers to be unable to participate in the study. The decision to use MMSE rather than other AD assessment scales, and the scoring ranges employed to classify patients as having mild-to-moderate or severe AD, reflect the latest guidelines published by the National Institute for Health and Clinical Experience (NICE) for rivastigmine treatment in AD patients.<a class="elsevierStyleCrossRef" href="#bib0065">13</a>During the same inclusion visit, and after receiving the caregiver's written informed consent statement, researchers proceeded to take down data. The main variable, the caregiver's user experience with transdermal rivastigmine, was measured using an ad hoc questionnaire. As secondary variables, researchers recorded the caregiver's demographic and care arrangement data (including time as patient's caregiver, daily hours dedicated to care activities, number of daily medications, and time spent preparing and administering treatment). The researcher's user experience and the caregiver's and the researcher's satisfaction with treatment were documented using ad hoc questionnaires similar to the one used for the main variable. Overall caregiver satisfaction was evaluated quantitatively and qualitatively; caregivers rated satisfaction between 1 (very satisfied) and 5 (very unsatisfied). Doctor satisfaction, whether overall or satisfaction with patch efficacy and tolerability, was scored from 1 (no satisfaction) to 10 (maximum satisfaction). Caregiver preference for treatment was evaluated using the question “What form of rivastigmine treatment do you prefer?” Caregivers were able to choose between ‘oral’ and ‘transdermal’. Improvements in the patient, whether perceived by caregivers or doctors, were evaluated using the Clinical Global Impressions-Change scale (CGI-C).<a class="elsevierStyleCrossRef" href="#bib0070">14</a> This questionnaire consists of a single question comparing the patient's general states of health under the current and the previous treatments. There are 7 possible responses ranging from ‘much better’ to ‘much worse’. Treatment adherence was evaluated using a Morisky adherence scale.<a class="elsevierStyleCrossRef" href="#bib0075">15</a> This questionnaire includes 2 questions to measure forgetfulness and commitment to providing care, and 2 others to determine whether treatment was interrupted at any time and if the respondent understands the long-term benefits of the medication. A single suboptimal answer served to classify the respondent as showing poor adherence. Since this questionnaire was originally designed for use by patients, we adapted it for use by caregivers and to specifically address transdermal rivastigmine treatment. We also added a question to determine the frequency with which caregivers forgot to administer treatment. Researchers followed the Declaration of Helsinki and Good Clinical Practice guidelines at all times. The study was approved by the Clinical Research Ethics Committee at Hospital Universitari de Bellvitge (L’Hospitalet de Llobregat, Barcelona).Statistical analysis was completed using SAS statistics software for Windows, version 9.2. The analysis included all carers who met selection criteria and for whom there were valid data for the main variable. Substitution methods were not employed for missing data. Discrete qualitative and quantitative variables were described as absolute frequencies (n) and relative frequencies (percentages). Continuous quantitative variables were described as the mean±standard deviation (SD). The chi-square test was used to assess differences in the CGI-C scale scores given by informal caregivers and doctors.ResultsPopulation characteristicsThe study recruited a total of 1975 informal caregivers. Of these caregivers, 89 were excluded due to not meeting selection criteria, and 35 were excluded because they lacked experience with transdermal rivastigmine. In the end, 1851 caregivers and 239 doctors from 198 centres were included. <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> summarises the characteristics of both the caregivers and the care they provide.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>User experience<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a> displays the most important findings regarding caregivers’ user experience for transdermal rivastigmine. The most common areas for patch application were the chest, arms, and dorsal-lumbar region (data not shown). Most caregivers (94.7%) reported changing patches daily.<elsevierMultimedia ident="tbl0010"></elsevierMultimedia>Researchers’ experience is summarised in <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>. More than half of the patients treated with rivastigmine received it in transdermal form. Most patients in this subgroup remained on the same treatment 6 months after having started it. The majority of the researchers recorded that patients and caregivers preferred transdermal treatment and found it easier to use than the oral form. The main reasons cited by patients for leaving or not beginning transdermal treatment are summarised in <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>.<elsevierMultimedia ident="tbl0015"></elsevierMultimedia><elsevierMultimedia ident="fig0005"></elsevierMultimedia>Treatment satisfaction and preferencesMost caregivers and doctors expressed overall satisfaction with transdermal treatment (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). Caregivers scored their satisfaction level at 2.6±0.4 points. Most caregivers rated using the patch as easy or very easy (92.8%) and assigned a similar rating to following the treatment schedule (94%). However, only 65% rated the patch as easy for patients to apply by themselves. Most caregivers indicated that administering transdermal treatment interfered little or not at all in their daily routine (77.4%) or the patient's daily routine (78.6%). Assessment of caregiver preference for rivastigmine routes of delivery showed that this group clearly favoured the transdermal form (94.3%). Among doctors, 90% had medium-to-high hopes for the rivastigmine patch before beginning to use it; approximately 92% declared that the product delivered the results they had expected. Almost all of the professionals (90.9%) rated the treatment as easy based on the opinions expressed by their patients. Clinical efficacy earned a mean score of 7.4±1.33 points. Cutaneous tolerability had a mean score of 7.0±1.48 points; gastrointestinal, 8.8±0.96; and overall tolerability, 8.1±0.93.<elsevierMultimedia ident="fig0010"></elsevierMultimedia>CGI-C scaleCaregivers’ and doctors’ opinions on the patient's state of health under the new treatment compared to the previous treatment are shown in <a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>. In general, both groups considered that patients had remained stable or shown improvement, although informal caregivers perceived significantly greater degrees of improvement than doctors did.<elsevierMultimedia ident="fig0015"></elsevierMultimedia>ComplianceFifty-seven per cent of the caregivers were categorised as compliant. The factor with the greatest impact on treatment compliance was the tendency among caregivers to stop administering the drug if patients experienced adverse events. The forgetfulness rate was low when patients were treated with rivastigmine patches. Results from the adherence questionnaire are shown in <a class="elsevierStyleCrossRef" href="#fig0020">Fig. 4</a>.<elsevierMultimedia ident="fig0020"></elsevierMultimedia>DiscussionThe characteristics of the caregivers assessed in this study coincide with those found by another recent study in our region that examined carers of patients treated with AChEI.<a class="elsevierStyleCrossRef" href="#bib0080">16</a> Most were women about 60 years of age, with a primary education and actively employed. Roughly 80% shared a household with their patients and spent a mean of 10hours daily caring for them.Generally speaking, caregivers expressed satisfaction with transdermal treatment and considered that instructions were easy to follow and patches were easy to apply. Concurring with these results, a recent randomised study<a class="elsevierStyleCrossRef" href="#bib0060">12</a> found that 93% of patients (or their caregivers) who had been receiving high doses of oral rivastigmine and who switched directly to high transdermal doses found the patches easy or very easy to use; 95.4% found the treatment schedule easy or very easy to follow. In our case, ease of use as perceived by caregivers was also consistent with ease of use reported by doctors.Most of the caregivers expressed satisfaction with transdermal treatment, as was the case in the randomised study mentioned above.<a class="elsevierStyleCrossRef" href="#bib0060">12</a> In that study, 90.7% of patients/caregivers who switched from high-dose oral rivastigmine to a transdermal form were satisfied with the patches; in contrast, 79.1% of patients who continued with oral treatment were satisfied (P=.0001). In our study, doctors expressed a higher degree of overall satisfaction than carers (92.9% vs. 76.5%; P<.0001). This discrepancy may be explained by a number of factors. On the one hand, the question used to evaluate overall satisfaction differed between these groups, and each had different possible responses. On the other hand, the factors that determine satisfaction with treatment probably differ between caregivers and health professionals. For caregivers, satisfaction tends to depend on whether the treatment is user friendly and how it affects activities of daily life.<a class="elsevierStyleCrossRefs" href="#bib0035">7,11,17</a> It is quite unlikely that a health professional would rate these considerations as more important than treatment efficacy or safety on a satisfaction questionnaire. Caregivers were not optimistic that their patients would be able to self-administer their patches but we should point out that if AD patients were able to do so, it would decrease the burden on their caregivers. This could be a decisive factor for satisfaction in this group, considering that a large percentage of the carers in this study were actively employed.The study showed that CGI-C scores reported by both doctors and informal caregivers of AD patients are similar. When these scores are compared to objective measuring instruments, however, we see that caregivers tend to overestimate neurological decline in their patients.<a class="elsevierStyleCrossRef" href="#bib0090">18</a> In this study, most caregivers reported improvement among patients after switching from oral to transdermal rivastigmine, and they were significantly more likely to do so than doctors (61.4% vs. 53.1%; P<.0001). Nevertheless, no objective measurements of patient decline were performed that would enable us to assess these perceptions, nor did we evaluate the correlation between their opinion and the doctors’ opinion. In contrast, some of the caregivers did not perceive any differences in the status of the patient with respect to the previous treatment. Caregivers are not always conscious of the fact that efficacy of an AD treatment often manifests as stabilisation of the patient's state.<a class="elsevierStyleCrossRef" href="#bib0095">19</a> This lack of improvement perceived by some caregivers in our study may affect their level of satisfaction with the patch. It suggests that clear communication between doctor and caregiver is needed in order to create realistic expectations for the treatment.Patients treated with oral AChEI generally display low persistence. A retrospective<a class="elsevierStyleCrossRef" href="#bib0100">20</a> study estimated that only 30.8% of patients remained in treatment with AChEI 6 months after having started; use of low doses was cited as a risk factor for stopping treatment. In our case, persistence with transdermal rivastigmine reported at the 6-month mark was 87.3%. This considerably higher figure may be partially due to the fact that all patients received high doses of rivastigmine. Nevertheless, the inherent advantages of the transdermal route are also likely to have had a strong impact.The most frequent reason for stopping treatment was local skin reaction. Although these are the most frequent reactions caused by treatment with transdermal drugs, they tend to be mild to moderate in the case of rivastigmine patches.<a class="elsevierStyleCrossRefs" href="#bib0105">21,22</a> Cutaneous reactions can be lessened by changing patches daily, and almost all caregivers in the study complied with this guideline. In addition, simple patient care routines, such as removing the patch carefully and using emollients and topical corticosteroids, decrease the impact of skin reactions.<a class="elsevierStyleCrossRef" href="#bib0115">23</a> In addition, there were few cases of stopping transdermal treatment due to gastrointestinal disorders or other adverse effects, which confirms the good tolerability of this route.Despite the high percentage of treatment permanence, we observed only moderate treatment compliance (57%). We did not record compliance for the patients’ previous period of oral treatment. Based on published evidence, however, it would be reasonable to think that compliance with transdermal treatment would be higher, or at least that causes of poor compliance would be more easily avoidable than in oral treatment. In an earlier prospective observational study in patients with poor adherence to oral treatment,<a class="elsevierStyleCrossRef" href="#bib0120">24</a> researchers found that treatment compliance increased as patients switched from oral to transdermal treatment. When the percentage of patch users was at 64.8%, treatment compliance had reached 73.6%.<a class="elsevierStyleCrossRef" href="#bib0120">24</a> This figure is higher than that obtained by our study. In part, the difference could be due to the way compliance was assessed. In the prospective study, patients were considered compliant if they forgot <20% of their doses and took their medication as prescribed >80% of the time.Researchers have observed that patients taking tablets were more likely to forget their dose than patients using patches.<a class="elsevierStyleCrossRef" href="#bib0120">24</a> This study shows a low rate of forgotten doses; in fact, most of the caregivers classified as non-compliant made a conscious decision not to adhere to treatment. More than a third temporarily suspended the patches when patients experienced adverse events. The same cause of treatment non-compliance has been reported among patients taking oral medications for chronic illnesses that resemble AD in that treatment benefits are not immediately apparent.<a class="elsevierStyleCrossRef" href="#bib0125">25</a> This may indicate that caregivers for patients with AD will require additional training about the long-term benefits of treatment so that patients’ experience with the transdermal route will yield optimal results.In conclusion, most informal caregivers preferred transdermal rivastigmine to oral rivastigmine. Caregivers reported few incidents of forgetting doses and they indicated that the patch was easy to use and apply with little impact on the carer's daily routine. Most caregivers expressed satisfaction with transdermal treatment, and like the doctors, they perceived overall improvement in patients who had switched from the previous treatment. Studies report positive user experience results, acceptance of the transdermal form, and acceptable tolerability of the rivastigmine patch at high doses (9.5mg/day) in patients with AD who had previously been treated with high oral doses (9–12mg/day). One implication of these data is that it may be beneficial to market rivastigmine patches with higher doses (13.3mg/day), as has been confirmed by more recent randomised trials.<a class="elsevierStyleCrossRef" href="#bib0130">26</a>FundingThis study received financial support from Novartis Farmacéutica, S.A.Conflicts of interestJavier Ricart and Basilio Hernández are employed by Novartis Farmacéutica, SA. Ramón Reñé has no conflicts of interest to declare with regard to this study." "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:2 [ "identificador" => "xres318939" "titulo" => array:5 [ 0 => "Abstract" 1 => "Introduction" 2 => "Methods" 3 => "Results" 4 => "Conclusions" ] ] 1 => array:2 [ "identificador" => "xpalclavsec301739" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres318938" "titulo" => array:5 [ 0 => "Resumen" 1 => "Introducción" 2 => "Métodos" 3 => "Resultados" 4 => "Conclusiones" ] ] 3 => array:2 [ "identificador" => "xpalclavsec301740" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Patients and methods" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "Results" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Population characteristics" ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "User experience" ] 2 => array:2 [ "identificador" => "sec0030" "titulo" => "Treatment satisfaction and preferences" ] 3 => array:2 [ "identificador" => "sec0035" "titulo" => "CGI-C scale" ] 4 => array:2 [ "identificador" => "sec0040" "titulo" => "Compliance" ] ] ] 7 => array:2 [ "identificador" => "sec0045" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0050" "titulo" => "Funding" ] 9 => array:2 [ "identificador" => "sec0055" "titulo" => "Conflicts of interest" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2012-10-01" "fechaAceptado" => "2013-02-19" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec301739" "palabras" => array:7 [ 0 => "Alzheimer disease" 1 => "Informal caregiver" 2 => "Rivastigmine" 3 => "Satisfaction" 4 => "Clinical Global Impression of Change" 5 => "Treatment compliance" 6 => "Transdermal patch" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec301740" "palabras" => array:7 [ 0 => "Enfermedad de Alzheimer" 1 => "Cuidador informal" 2 => "Rivastigmina" 3 => "Satisfacción" 4 => "Impresión Clínica Global de Cambio" 5 => "Cumplimiento terapéutico" 6 => "Parche transdérmico" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "IntroductionRivastigmine, a treatment for mild to moderate Alzheimer disease (AD), is the first cholinesterase inhibitor to be available in the transdermal format. We aim to describe user experience and satisfaction with the rivastigmine patch, as well as any clinical changes perceived in patients. MethodsObservational, cross-sectional, multicentre study with 239 investigators and 1851 informal caregivers of patients with mild to moderate AD. Patients were treated with transdermal rivastigmine patches for ≥6 months and had previously received high doses of oral rivastigmine. ResultsMean caregiver age was 59.8±14.4years and 70.9% were women. They spent 10.0±7.1hours per day providing care and 79.8% lived with the patient. Patch instructions were described as easy to follow by 97.1% of the caregivers and 92.1% of them rated patch application as easy or very easy. The most commonly cited disadvantage was adhesion problems (26.8%). Discontinuation of treatment was due to cutaneous reactions in most cases. Overall, 76.5% of the caregivers were satisfied or very satisfied with transdermal treatment and 77.4% considered that its interference with daily activities was minimal or null. The patch was preferred to oral treatment by 94.3% of caregivers. Clinical Global Impression of Change ratings improved according to 61.3% of the caregivers and 53% of the investigators. Few caregivers reported medication forgetfulness. ConclusionsMost caregivers of patients with mild to moderate AD preferred the transdermal format of rivastigmine to the oral format. Caregivers also reported overall satisfaction, ease of use, and reduced impact on daily activities for transdermal rivastigmine format, in addition to patient improvement compared to their condition under the previous treatment." ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "IntroducciónRivastigmina, tratamiento para la enfermedad de Alzheimer (EA) leve-moderada, es el primer inhibidor de la colinesterasa administrable por vía transdérmica. Se describen la experiencia de uso y la satisfacción de los cuidadores informales con los parches de rivastigmina, así como el cambio clínico percibido en los pacientes con su empleo. MétodosEstudio observacional, transversal y multicéntrico, con 239 investigadores y 1851 cuidadores informales de pacientes con EA leve-moderada, tratados con rivastigmina transdérmica durante ≥6 meses, y que previamente recibían dosis altas de rivastigmina por vía oral. ResultadosLa edad media de los cuidadores fue 59,8±14,4 años (70,9% mujeres). El 79,8% compartía domicilio con el paciente, dedicando 10,0±7,1h/día a su cuidado. Para la mayoría de los cuidadores las instrucciones del parche fueron comprensibles (97,1%) y la aplicación fácil o muy fácil (92,1%). La principal dificultad mencionada fueron problemas de adhesión (26,8%). En general, los abandonos del tratamiento se produjeron por reacciones cutáneas. El 76,5% de los cuidadores estuvieron satisfechos o muy satisfechos con el parche y el 77,4% consideró que interfería poco o nada en las actividades diarias propias. El 94,3% prefirió la vía transdérmica respecto a la vía oral. La Impresión Clínica Global de Cambio fue mejor en algún grado para el 61,3% de los cuidadores y para el 53% de los investigadores. Se notificaron pocos olvidos de la medicación. ConclusionesLa mayoría de los cuidadores de pacientes con EA leve-moderada prefirieron la vía transdérmica de rivastigmina a la vía oral, notificando satisfacción global, facilidad de uso e impacto reducido en sus actividades diarias propias con la ruta transdérmica, así como mejora de los pacientes respecto al tratamiento anterior." ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Reñé R, Ricart J, Hernández B, en representación de los investigadores del Estudio Experience. Experiencia de uso y satisfacción con rivastigmina transdérmica en cuidadores de pacientes con enfermedad de Alzheimer de leve a moderada previamente tratados con rivastigmina oral a dosis altas. Neurología. 2014;29:86–93." ] ] "multimedia" => array:7 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2279 "Ancho" => 2821 "Tamanyo" => 349480 ] ] "descripcion" => array:1 [ "en" => "Detailed reasons most frequently cited by caregivers of AD patients for not starting transdermal rivastigmine treatment (A) and for suspending transdermal rivastigmine treatment (B). Items 10 and 11 on the doctors’ ad hoc questionnaire reporting on user experience." ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1340 "Ancho" => 2799 "Tamanyo" => 264981 ] ] "descripcion" => array:1 [ "en" => "Caregivers’ and researchers’ overall satisfaction with the current treatment (rivastigmine patch) for patients with AD. Items 7 and 5 from the respective ad hoc questionnaires." ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1014 "Ancho" => 2392 "Tamanyo" => 122496 ] ] "descripcion" => array:1 [ "en" => "Clinical Global Impressions-Change (CGI-C) rating for patient status, provided by caregivers and doctors to compare patient health under current and previous treatments." ] ] 3 => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1392 "Ancho" => 3426 "Tamanyo" => 270018 ] ] "descripcion" => array:1 [ "en" => "Caregiver compliance with transdermal rivastigmine treatment. Adapted Morisky adherence scale." ] ] 4 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "SD: standard deviation." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Total carers N=1851 \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Carer characteristics</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age (years), mean±SD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">59.8±14.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sex (female), n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1313 (70.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Educational level, n (%)</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Primary education \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">807 (43.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Secondary education \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">508 (27.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Higher education \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">263 (14.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No studies \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">252 (13.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Employment status, n (%)</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Retired/Ineligible \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1173 (63.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Employed \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">628 (33.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Unemployed \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50 (2.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sharing household with patient (yes), n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1478 (79.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Care description</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Time spent as patient's carer (years, mean±SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.4±2.7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Time spent performing care tasks per day (hours, mean±SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10.0±7.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Number of medications administered daily±SD<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.0±4.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Time spent daily preparing and administering all of the patient's medications (hours, mean±SD) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.8±1.59 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab465340.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Includes all daily doses of the patient's medications (tablets, inhalers, patches, etc.)." ] ] ] "descripcion" => array:1 [ "en" => "Sociodemographic data from informal caregivers in the study; description of the care they provide to their patients." ] ] 5 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Carers’ experience \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Total carersN=1851 \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Responsible for applying the patch (carer), n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1697 (91.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clarity of the instructions for patch use, n (%)</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">‘Quite clear’ or ‘clear’ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1797 (97.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">‘Somewhat unclear’ or ‘completely unclear’ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">54.4 (2.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ease in applying the patch, n (%)</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">‘Very easy’ or ‘easy’ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1705 (92.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">‘Intermediate’ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">137 (7.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">‘Difficult’ or ‘very difficult’ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 (0.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Main reasons for difficulty, n (%)</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">The patch comes loose \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">20 (26.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Difficulty rotating patches to different locations \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 (15.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Difficulty opening the envelope \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13 (14.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Difficulties specific to individual carers<a class="elsevierStyleCrossRef" href="#tblfn0010">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (8.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Poor patient cooperation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (8.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dermatitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (7.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Presence of hair in the application area \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (3.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Whether the patch met initial expectations</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">‘Much better’ or ‘somewhat better’ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1173 (63.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">‘Neither better nor worse’ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">598 (32.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">‘Significantly worse’ or ‘much worse’ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">80 (4.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab465341.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "a" "nota" => "Mild parkinsonism, illiteracy, other." ] ] ] "descripcion" => array:1 [ "en" => "Carers’ experience with using high-dose transdermal rivastigmine as treatment for Alzheimer disease." ] ] 6 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "All items show the mean percentage (standard deviation) except where otherwise stated.AD: Alzheimer disease; AChEI: acetylcholinesterase inhibitors." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Doctors’ experience \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Total doctorsN=278 \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patients diagnosed with AD divided by total patients seen in the clinic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">27.9 (20.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Treated with AChEI<a class="elsevierStyleCrossRef" href="#tblfn0015">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">81.1 (16.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Treated with rivastigmine<a class="elsevierStyleCrossRef" href="#tblfn0015">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">54.5 (19.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Treated transdermally<a class="elsevierStyleCrossRef" href="#tblfn0015">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">67.7 (22.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Previously treated with oral rivastigmine<a class="elsevierStyleCrossRef" href="#tblfn0015">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42.2 (21.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Prior treatment with high-dose oral rivastigmine (9–12mg/day)<a class="elsevierStyleCrossRef" href="#tblfn0015">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">61.2 (27.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Percentage of the total patients treated with transdermal rivastigmine who remain on that treatment after 3 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">90.5 (10.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Percentage of the total patients treated with transdermal rivastigmine who remain on that treatment after 6 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">87.3 (11.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patients previously treated with oral rivastigmine who prefer the transdermal form \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">87.7 (12.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Doctors who report the transdermal form as being easier to use than the oral form, based on their patients’ opinions, n (%)<a class="elsevierStyleCrossRef" href="#tblfn0020">b</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">228 (90.5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab465339.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "a" "nota" => "Percentage calculated with respect to the previous item." ] 1 => array:3 [ "identificador" => "tblfn0020" "etiqueta" => "b" "nota" => "Percentage calculated with respect to the total responses obtained." ] ] ] "descripcion" => array:1 [ "en" => "Doctors’ experience with high-dose transdermal rivastigmine as treatment for Alzheimer disease based on results in their clinics." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:26 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EFNS guidelines for the diagnosis and management of Alzheimer's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Hort" 1 => "J.T. O’Brien" 2 => "G. Gainotti" 3 => "T. Pirttila" 4 => "B.O. Popescu" 5 => "I. Rektorova" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-1331.2010.03040.x" "Revista" => array:6 [ "tituloSerie" => "Eur J Neurol" "fecha" => "2010" "volumen" => "17" "paginaInicial" => "1236" "paginaFinal" => "1248" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20831773" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cholinesterase inhibitors for Alzheimer's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Birks" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Cochrane Database Syst Rev" "fecha" => "2006" "volumen" => "25" "paginaInicial" => "CD005593" "itemHostRev" => array:3 [ "pii" => "S0140673611604388" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M.W. Jann" 1 => "K.L. Shirley" 2 => "G.W. Small" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2165/00003088-200241100-00003" "Revista" => array:6 [ "tituloSerie" => "Clin Pharmacokinet" "fecha" => "2002" "volumen" => "41" "paginaInicial" => "719" "paginaFinal" => "739" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12162759" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "B.P. Imbimbo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "CNS Drugs" "fecha" => "2001" "volumen" => "15" "paginaInicial" => "375" "paginaFinal" => "390" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11475943" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0020729208001550" "estado" => "S300" "issn" => "00207292" ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J. Cummings" 1 => "B. Winblad" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/14737175.7.11.1457" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Neurother" "fecha" => "2007" "volumen" => "7" "paginaInicial" => "1457" "paginaFinal" => "1463" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17997695" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Kurz" 1 => "M. Farlow" 2 => "G. Lefèvre" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1742-1241.2009.02052.x" "Revista" => array:7 [ "tituloSerie" => "Int J Clin Pract" "fecha" => "2009" "volumen" => "63" "paginaInicial" => "799" "paginaFinal" => "805" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19392927" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673611607010" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease – rivastigmine patch versus capsule" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Winblad" 1 => "J. Cummings" 2 => "N. Andreasen" 3 => "G. Grossberg" 4 => "M. Onofrj" 5 => "C. Sadowsky" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/gps.1788" "Revista" => array:7 [ "tituloSerie" => "Int J Geriatr Psychiatry" "fecha" => "2007" "volumen" => "22" "paginaInicial" => "456" "paginaFinal" => "467" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17380489" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673610611890" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Grossberg" 1 => "C. Sadowsky" 2 => "H. Fröstl" 3 => "L. Frölich" 4 => "J. Nagel" 5 => "S. Tekin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Alzheimer Dis Assoc Disord" "fecha" => "2009" "volumen" => "23" "paginaInicial" => "158" "paginaFinal" => "164" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19484917" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Caregiver burden in Alzheimer's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "P.W. Slattum" 1 => "M.A. Johnson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Consult Pharm" "fecha" => "2004" "volumen" => "19" "paginaInicial" => "352" "paginaFinal" => "362" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16553479" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "R. Blesa" 1 => "C. Ballard" 2 => "J.M. Orgogozo" 3 => "R. Lane" 4 => "S.K. Thomas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1212/01.wnl.0000302372.08983.38" "Revista" => array:6 [ "tituloSerie" => "Neurology" "fecha" => "2007" "volumen" => "69" "paginaInicial" => "S23" "paginaFinal" => "S28" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18071154" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Winblad" 1 => "A.K. Kawata" 2 => "K.M. Beusterien" 3 => "S.K. Thomas" 4 => "A. Wimo" 5 => "R. Lane" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/gps.1806" "Revista" => array:6 [ "tituloSerie" => "Int J Geriatr Psychiatry" "fecha" => "2007" "volumen" => "22" "paginaInicial" => "485" "paginaFinal" => "491" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17407176" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluación de la conveniencia del cambio de vía de administración de rivastigmina en pacientes con enfermedad de Alzheimer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Blesa González" 1 => "M. Boada Rovira" 2 => "C. Martínez Parra" 3 => "D. Gil-Saladié" 4 => "C.A. Almagro" 5 => "A.L. Gobartt Vázquez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.nrl.2010.10.007" "Revista" => array:6 [ "tituloSerie" => "Neurología" "fecha" => "2011" "volumen" => "26" "paginaInicial" => "262" "paginaFinal" => "271" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21227548" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of NICE technology appraisal guidance 111)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "NICE technology appraisal guidance 217" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "fecha" => "2011" "editorial" => "National Institute for Health and Clinical Excellence" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:1 [ "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:2 [ "titulo" => "ECDEU assessment manual for psychopharmacology" "serieFecha" => "1976" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Concurrent and predictive validity of a self-reported measure of medication adherent" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D.E. Morisky" 1 => "L.W. Green" 2 => "D.M. Lewvine" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Medical Care" "fecha" => "1986" "volumen" => "24" "paginaInicial" => "67" "paginaFinal" => "74" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3945130" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Perfil del cuidador informal asociado al manejo clínico del paciente con enfermedad de Alzheimer no respondedor al tratamiento sintomático de la enfermedad" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.L. Molinuevo" 1 => "B. Hernández" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.nrl.2011.05.011" "Revista" => array:7 [ "tituloSerie" => "Neurología" "fecha" => "2011" "volumen" => "26" "paginaInicial" => "518" "paginaFinal" => "527" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21803459" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673604166816" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Donepecilo bucodispersable: ¿están los cuidadores principales del paciente con enfermedad de Alzheimer más satisfechos que con la formulación tradicional de donepecilo?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C. Sevilla" 1 => "P.E. Jiménez-Caballero" 2 => "V. Alfonso" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Neurol" "fecha" => "2009" "volumen" => "49" "paginaInicial" => "451" "paginaFinal" => "457" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19859884" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Differences between physician and caregiver evaluations in Alzheimer's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "E. Sinforiani" 1 => "C. Pasotti" 2 => "L. Chiapella" 3 => "P. Malinverni" 4 => "C. Zucchella" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Funct Neurol" "fecha" => "2010" "volumen" => "25" "paginaInicial" => "205" "paginaFinal" => "209" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21388581" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cholinesterase inhibitors stabilize Alzheimer's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "E. Giacobini" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann N Y Acad Sci" "fecha" => "2000" "volumen" => "920" "paginaInicial" => "321" "paginaFinal" => "327" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11193171" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: a retrospective cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "E. Kröger" 1 => "R. van Marum" 2 => "P. Souverein" 3 => "T. Egberts" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2165/11538230-000000000-00000" "Revista" => array:6 [ "tituloSerie" => "Drugs Aging" "fecha" => "2010" "volumen" => "27" "paginaInicial" => "663" "paginaFinal" => "675" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20658794" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Skin tolerability associated with transdermal drug delivery systems: an overview" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "I. Ale" 1 => "J.M. Lachapelle" 2 => "H.I. Maibach" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12325-009-0075-9" "Revista" => array:6 [ "tituloSerie" => "Adv Ther" "fecha" => "2009" "volumen" => "26" "paginaInicial" => "920" "paginaFinal" => "935" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19967501" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J.L. Cummings" 1 => "M.R. Farlow" 2 => "X. Meng" 3 => "S. Tekin" 4 => "J.T. Olin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Drug Invest" "fecha" => "2010" "volumen" => "30" "paginaInicial" => "41" "paginaFinal" => "49" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Transdermal rivastigmine: management of cutaneous adverse events and review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J. Greenspon" 1 => "N. Herrmann" 2 => "D.N. Adam" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2165/11592230-000000000-00000" "Revista" => array:6 [ "tituloSerie" => "CNS Drugs" "fecha" => "2011" "volumen" => "25" "paginaInicial" => "575" "paginaFinal" => "583" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21623641" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluación de las estrategias para mejorar el cumplimiento terapéutico en la práctica clínica habitual en pacientes incumplidores con demencia tipo Alzheimer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.L. Molinuevo" 1 => "F.J. Arranz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Neurol" "fecha" => "2012" "volumen" => "54" "paginaInicial" => "65" "paginaFinal" => "73" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22234564" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "G. Small" 1 => "B. Dubois" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Curr Res Med Opin" "fecha" => "2007" "volumen" => "23" "paginaInicial" => "2705" "paginaFinal" => "2713" ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10cm2) in Alzheimer's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Cummings" 1 => "L. Froelich" 2 => "S.E. Black" 3 => "S. Bakchine" 4 => "G. Bellelli" 5 => "J.L. Molinuevo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000340056" "Revista" => array:6 [ "tituloSerie" => "Dement Geriatr Cogn Disord" "fecha" => "2012" "volumen" => "33" "paginaInicial" => "341" "paginaFinal" => "353" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22796905" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735808/0000002900000002/v1_201403090041/S217358081300182X/v1_201403090041/en/main.assets" "Apartado" => array:4 [ "identificador" => "17109" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "CO1" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735808/0000002900000002/v1_201403090041/S217358081300182X/v1_201403090041/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217358081300182X?idApp=UINPBA00004N"]

Statistics

Original article

Experiencia de uso y satisfacción con rivastigmina transdérmica en cuidadores de pacientes con enfermedad de Alzheimer de leve a moderada previamente tratados con rivastigmina oral a dosis altas

R. Reñéa,

Corresponding author

udtd@bellvitgehospital.cat

Corresponding author.

, J. Ricartb, B. Hernándezb, representing researchers in the Experience study

a Unidad de Diagnóstico y Tratamiento de las Demencias, Servicio de Neurología, Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

b Departamento Médico, Novartis Farmacéutica, S.A., Barcelona, Spain

Read

4553

Times
was read the article

1145

Total PDF

3408

Total HTML

Share statistics

 array:25 [
  "pii" => "S217358081300182X"
  "issn" => "21735808"
  "doi" => "10.1016/j.nrleng.2013.12.004"
  "estado" => "S300"
  "fechaPublicacion" => "2014-03-01"
  "aid" => "480"
  "copyright" => "Sociedad Espa&#241;ola de Neurolog&#237;a"
  "copyrightAnyo" => "2012"
  "documento" => "article"
  "crossmark" => 0
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Neurologia. 2014;29:86-93"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 2340
    "formatos" => array:3 [
      "EPUB" => 43
      "HTML" => 1714
      "PDF" => 583
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:20 [
      "pii" => "S0213485313000571"
      "issn" => "02134853"
      "doi" => "10.1016/j.nrl.2013.02.012"
      "estado" => "S300"
      "fechaPublicacion" => "2014-03-01"
      "aid" => "480"
      "copyright" => "Sociedad Espa&#241;ola de Neurolog&#237;a"
      "documento" => "article"
      "crossmark" => 0
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Neurologia. 2014;29:86-93"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 4478
        "formatos" => array:3 [
          "EPUB" => 47
          "HTML" => 3614
          "PDF" => 817
        ]
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Original</span>"
        "titulo" => "Experiencia de uso y satisfacci&#243;n con rivastigmina transd&#233;rmica en cuidadores de pacientes con enfermedad de Alzheimer de leve a moderada previamente tratados con rivastigmina oral a dosis altas"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "86"
            "paginaFinal" => "93"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "From high doses of oral rivastigmine to transdermal rivastigmine patches&#58; user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0015"
            "etiqueta" => "Figura 3"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr3.jpeg"
                "Alto" => 1014
                "Ancho" => 2392
                "Tamanyo" => 133749
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Impresi&#243;n Cl&#237;nica Global de Cambio &#40;ICG-C&#41; en el estado de los pacientes&#44; notificada por cuidadores e investigadores y respecto al tratamiento anterior&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "R&#46; Re&#241;&#233;, J&#46; Ricart, B&#46; Hern&#225;ndez"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "R&#46;"
                "apellidos" => "Re&#241;&#233;"
              ]
              1 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Ricart"
              ]
              2 => array:2 [
                "nombre" => "B&#46;"
                "apellidos" => "Hern&#225;ndez"
              ]
              3 => array:1 [
                "colaborador" => "en representaci&#243;n de los investigadores del Estudio Experience"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S217358081300182X"
          "doi" => "10.1016/j.nrleng.2013.12.004"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217358081300182X?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485313000571?idApp=UINPBA00004N"
      "url" => "/02134853/0000002900000002/v1_201403030022/S0213485313000571/v1_201403030022/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:20 [
    "pii" => "S2173580814000108"
    "issn" => "21735808"
    "doi" => "10.1016/j.nrleng.2013.02.002"
    "estado" => "S300"
    "fechaPublicacion" => "2014-03-01"
    "aid" => "481"
    "copyright" => "Sociedad Espa&#241;ola de Neurolog&#237;a"
    "documento" => "article"
    "crossmark" => 0
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Neurologia. 2014;29:94-101"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 2770
      "formatos" => array:3 [
        "EPUB" => 51
        "HTML" => 2126
        "PDF" => 593
      ]
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
      "titulo" => "Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy&#58; preliminary results"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "94"
          "paginaFinal" => "101"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Estudio postautorizaci&#243;n de la eslicarbazepina en el tratamiento de epilepsias farmacorresistentes&#58; resultados preliminares"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0020"
          "etiqueta" => "Figure 4"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr4.jpeg"
              "Alto" => 1459
              "Ancho" => 1653
              "Tamanyo" => 113260
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Patients with adverse effects &#40;AE&#41; during ESL treatment &#40;<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>61&#41;&#44; specifying which AEs were not transient &#40;some patients experienced more than one type of AE&#41;&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A&#46; Massot, R&#46; Vivanco, A&#46; Principe, J&#46; Roquer, R&#46; Rocamora"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Massot"
            ]
            1 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Vivanco"
            ]
            2 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Principe"
            ]
            3 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Roquer"
            ]
            4 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Rocamora"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0213485313000583"
        "doi" => "10.1016/j.nrl.2013.02.013"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485313000583?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580814000108?idApp=UINPBA00004N"
    "url" => "/21735808/0000002900000002/v1_201403090041/S2173580814000108/v1_201403090041/en/main.assets"
  ]
  "itemAnterior" => array:20 [
    "pii" => "S2173580814000091"
    "issn" => "21735808"
    "doi" => "10.1016/j.nrleng.2013.02.001"
    "estado" => "S300"
    "fechaPublicacion" => "2014-03-01"
    "aid" => "478"
    "copyright" => "Sociedad Espa&#241;ola de Neurolog&#237;a"
    "documento" => "article"
    "crossmark" => 0
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Neurologia. 2014;29:76-85"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 3320
      "formatos" => array:3 [
        "EPUB" => 65
        "HTML" => 2679
        "PDF" => 576
      ]
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
      "titulo" => "Bradycardia in frontotemporal dementia"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "76"
          "paginaFinal" => "85"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Bradicardia en la demencia frontotemporal"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0015"
          "etiqueta" => "Figure 3"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr3.jpeg"
              "Alto" => 1125
              "Ancho" => 1500
              "Tamanyo" => 257579
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Brain MRI in a patient with FTD and bradycardia&#46; Female patient aged 65 with a 3-year history of FTD-behavioural variant&#46; Readings of 39 and 51<span class="elsevierStyleHsp" style=""></span>bpm in 2 consecutive consultations&#46; Coronal inversion recovery sequences&#46; Note the marked atrophy of the right temporal lobe&#46; In the lower section&#44; the dotted area marks the amygdala and the striped area marks the insular cortex&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A&#46; Robles Bay&#243;n, F&#46; Gude Sampedro, J&#46;M&#46; Torregrosa Quesada"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Robles Bay&#243;n"
            ]
            1 => array:2 [
              "nombre" => "F&#46;"
              "apellidos" => "Gude Sampedro"
            ]
            2 => array:2 [
              "nombre" => "J&#46;M&#46;"
              "apellidos" => "Torregrosa Quesada"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0213485313000558"
        "doi" => "10.1016/j.nrl.2013.02.010"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485313000558?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580814000091?idApp=UINPBA00004N"
    "url" => "/21735808/0000002900000002/v1_201403090041/S2173580814000091/v1_201403090041/en/main.assets"
  ]
  "en" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
    "titulo" => "From high doses of oral rivastigmine to transdermal rivastigmine patches&#58; user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "86"
        "paginaFinal" => "93"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "R&#46; Re&#241;&#233;, J&#46; Ricart, B&#46; Hern&#225;ndez"
        "autores" => array:4 [
          0 => array:4 [
            "nombre" => "R&#46;"
            "apellidos" => "Re&#241;&#233;"
            "email" => array:1 [
              0 => "udtd&#64;bellvitgehospital&#46;cat"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">¿</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "J&#46;"
            "apellidos" => "Ricart"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "B&#46;"
            "apellidos" => "Hern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          3 => array:1 [
            "colaborador" => "representing researchers in the Experience study"
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Unidad de Diagn&#243;stico y Tratamiento de las Demencias&#44; Servicio de Neurolog&#237;a&#44; Hospital Universitario de Bellvitge&#44; L&#8217;Hospitalet de Llobregat&#44; Barcelona&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Departamento M&#233;dico&#44; Novartis Farmac&#233;utica&#44; S&#46;A&#46;&#44; Barcelona&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Experiencia de uso y satisfacci&#243;n con rivastigmina transd&#233;rmica en cuidadores de pacientes con enfermedad de Alzheimer de leve a moderada previamente tratados con rivastigmina oral a dosis altas"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1340
            "Ancho" => 2799
            "Tamanyo" => 264981
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Caregivers&#8217; and researchers&#8217; overall satisfaction with the current treatment &#40;rivastigmine patch&#41; for patients with AD&#46; Items 7 and 5 from the respective ad hoc questionnaires&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Treatment for mild to moderate Alzheimer disease &#40;AD&#41; is based on oral acetylcholinesterase inhibitors &#40;AChEI&#41; such as rivastigmine&#44; donepezil&#44; and galantamine&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> These drugs have been shown to exert a dose-dependent beneficial effect on cognitive function&#46;<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2&#44;3</span></a> However&#44; the incidence of adverse events also increases with the dose&#8212;especially when there is no prior dose adjustment period&#8212;and with the peak plasma concentrations resulting from oral administration&#46;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> The first transdermal treatment for AD has now been approved&#58; a rivastigmine patch<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> that continuously releases the drug over the 24<span class="elsevierStyleHsp" style=""></span>hours after application&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> Dosed at 9&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#44; this patch has an effect equivalent to that of higher doses of oral rivastigmine&#44; and it is associated with fewer adverse gastrointestinal effects&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> It has also been shown that patients treated with high doses of oral rivastigmine may change directly to the transdermal patch dosed at 9&#46;5<span class="elsevierStyleHsp" style=""></span>ml&#47;day with no need for a prior adjustment period and without experiencing further adverse effects&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Treatment for patients with AD is generally managed by caregivers&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> As a result&#44; their assessment of treatment efficacy and the workload generated by the treatment may have a decisive effect on efforts to improve treatment compliance and ensure that the patient obtains the greatest benefit from the drugs prescribed&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> Earlier studies have reported a better user experience&#44; higher satisfaction&#44; and less interference in the carer&#39;s daily activities with transdermal rivastigmine than with oral rivastigmine&#46;<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">11&#44;12</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">The purpose of our study was to report on user experience with high doses of transdermal rivastigmine among informal caregivers of patients with mild to moderate AD&#46; Likewise&#44; we gathered data about caregiver satisfaction and preferences regarding the transdermal route&#44; any improvements perceived in patients after the change from oral treatment&#44; and treatment adherence&#46; At the same time&#44; we analysed user experience&#44; satisfaction&#44; and any perceived improvements in patients treated transdermally as reported by healthcare professionals treating patients with AD&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Patients and methods</span><p id="par0020" class="elsevierStylePara elsevierViewall">This cross-sectional multi-centre observational study was carried out across Spain&#46; During a 6-month period&#44; informal caregivers were recruited consecutively during routine visits to different participating neurology&#44; psychiatry&#44; or geriatric care clinics&#46; Inclusion criteria were as follows&#58; &#40;a&#41; caring for a patient with mild to moderate AD &#40;defined as a score &#8805;10 and &#60;26 on the Mini-Mental State Exam &#91;MMSE&#93;&#41; who was on stable treatment during &#8805;6 months with the highest approved dose of transdermal rivastigmine &#40;9&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#41;&#44; and who previously had received high doses of oral rivastigmine &#40;9&#8211;12<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#41;&#59; &#40;b&#41; having cared for the patient for at least 1 year&#59; &#40;c&#41; being responsible for managing the patient&#39;s medications&#44; and &#40;d&#41; being able to provide accurate information about the study variables&#46; We excluded caregivers of patients with severe AD &#40;MMSE<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>10&#41; or dementia of other causes&#44; paid caregivers&#44; and those considered by researchers to be unable to participate in the study&#46; The decision to use MMSE rather than other AD assessment scales&#44; and the scoring ranges employed to classify patients as having mild-to-moderate or severe AD&#44; reflect the latest guidelines published by the National Institute for Health and Clinical Experience &#40;NICE&#41; for rivastigmine treatment in AD patients&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">During the same inclusion visit&#44; and after receiving the caregiver&#39;s written informed consent statement&#44; researchers proceeded to take down data&#46; The main variable&#44; the caregiver&#39;s user experience with transdermal rivastigmine&#44; was measured using an ad hoc questionnaire&#46; As secondary variables&#44; researchers recorded the caregiver&#39;s demographic and care arrangement data &#40;including time as patient&#39;s caregiver&#44; daily hours dedicated to care activities&#44; number of daily medications&#44; and time spent preparing and administering treatment&#41;&#46; The researcher&#39;s user experience and the caregiver&#39;s and the researcher&#39;s satisfaction with treatment were documented using ad hoc questionnaires similar to the one used for the main variable&#46; Overall caregiver satisfaction was evaluated quantitatively and qualitatively&#59; caregivers rated satisfaction between 1 &#40;very satisfied&#41; and 5 &#40;very unsatisfied&#41;&#46; Doctor satisfaction&#44; whether overall or satisfaction with patch efficacy and tolerability&#44; was scored from 1 &#40;no satisfaction&#41; to 10 &#40;maximum satisfaction&#41;&#46; Caregiver preference for treatment was evaluated using the question &#8220;What form of rivastigmine treatment do you prefer&#63;&#8221; Caregivers were able to choose between &#8216;oral&#8217; and &#8216;transdermal&#8217;&#46; Improvements in the patient&#44; whether perceived by caregivers or doctors&#44; were evaluated using the Clinical Global Impressions-Change scale &#40;CGI-C&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> This questionnaire consists of a single question comparing the patient&#39;s general states of health under the current and the previous treatments&#46; There are 7 possible responses ranging from &#8216;much better&#8217; to &#8216;much worse&#8217;&#46; Treatment adherence was evaluated using a Morisky adherence scale&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> This questionnaire includes 2 questions to measure forgetfulness and commitment to providing care&#44; and 2 others to determine whether treatment was interrupted at any time and if the respondent understands the long-term benefits of the medication&#46; A single suboptimal answer served to classify the respondent as showing poor adherence&#46; Since this questionnaire was originally designed for use by patients&#44; we adapted it for use by caregivers and to specifically address transdermal rivastigmine treatment&#46; We also added a question to determine the frequency with which caregivers forgot to administer treatment&#46; Researchers followed the Declaration of Helsinki and Good Clinical Practice guidelines at all times&#46; The study was approved by the Clinical Research Ethics Committee at Hospital Universitari de Bellvitge &#40;L&#8217;Hospitalet de Llobregat&#44; Barcelona&#41;&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Statistical analysis was completed using SAS statistics software for Windows&#44; version 9&#46;2&#46; The analysis included all carers who met selection criteria and for whom there were valid data for the main variable&#46; Substitution methods were not employed for missing data&#46; Discrete qualitative and quantitative variables were described as absolute frequencies &#40;<span class="elsevierStyleItalic">n</span>&#41; and relative frequencies &#40;percentages&#41;&#46; Continuous quantitative variables were described as the mean<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>standard deviation &#40;SD&#41;&#46; The chi-square test was used to assess differences in the CGI-C scale scores given by informal caregivers and doctors&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Results</span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Population characteristics</span><p id="par0035" class="elsevierStylePara elsevierViewall">The study recruited a total of 1975 informal caregivers&#46; Of these caregivers&#44; 89 were excluded due to not meeting selection criteria&#44; and 35 were excluded because they lacked experience with transdermal rivastigmine&#46; In the end&#44; 1851 caregivers and 239 doctors from 198 centres were included&#46; <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> summarises the characteristics of both the caregivers and the care they provide&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">User experience</span><p id="par0040" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a> displays the most important findings regarding caregivers&#8217; user experience for transdermal rivastigmine&#46; The most common areas for patch application were the chest&#44; arms&#44; and dorsal-lumbar region &#40;data not shown&#41;&#46; Most caregivers &#40;94&#46;7&#37;&#41; reported changing patches daily&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0045" class="elsevierStylePara elsevierViewall">Researchers&#8217; experience is summarised in <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#46; More than half of the patients treated with rivastigmine received it in transdermal form&#46; Most patients in this subgroup remained on the same treatment 6 months after having started it&#46; The majority of the researchers recorded that patients and caregivers preferred transdermal treatment and found it easier to use than the oral form&#46; The main reasons cited by patients for leaving or not beginning transdermal treatment are summarised in <a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Treatment satisfaction and preferences</span><p id="par0050" class="elsevierStylePara elsevierViewall">Most caregivers and doctors expressed overall satisfaction with transdermal treatment &#40;<a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>&#41;&#46; Caregivers scored their satisfaction level at 2&#46;6<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>0&#46;4 points&#46; Most caregivers rated using the patch as easy or very easy &#40;92&#46;8&#37;&#41; and assigned a similar rating to following the treatment schedule &#40;94&#37;&#41;&#46; However&#44; only 65&#37; rated the patch as easy for patients to apply by themselves&#46; Most caregivers indicated that administering transdermal treatment interfered little or not at all in their daily routine &#40;77&#46;4&#37;&#41; or the patient&#39;s daily routine &#40;78&#46;6&#37;&#41;&#46; Assessment of caregiver preference for rivastigmine routes of delivery showed that this group clearly favoured the transdermal form &#40;94&#46;3&#37;&#41;&#46; Among doctors&#44; 90&#37; had medium-to-high hopes for the rivastigmine patch before beginning to use it&#59; approximately 92&#37; declared that the product delivered the results they had expected&#46; Almost all of the professionals &#40;90&#46;9&#37;&#41; rated the treatment as easy based on the opinions expressed by their patients&#46; Clinical efficacy earned a mean score of 7&#46;4<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>1&#46;33 points&#46; Cutaneous tolerability had a mean score of 7&#46;0<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>1&#46;48 points&#59; gastrointestinal&#44; 8&#46;8<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>0&#46;96&#59; and overall tolerability&#44; 8&#46;1<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>0&#46;93&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">CGI-C scale</span><p id="par0055" class="elsevierStylePara elsevierViewall">Caregivers&#8217; and doctors&#8217; opinions on the patient&#39;s state of health under the new treatment compared to the previous treatment are shown in <a class="elsevierStyleCrossRef" href="#fig0015">Fig&#46; 3</a>&#46; In general&#44; both groups considered that patients had remained stable or shown improvement&#44; although informal caregivers perceived significantly greater degrees of improvement than doctors did&#46;</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Compliance</span><p id="par0060" class="elsevierStylePara elsevierViewall">Fifty-seven per cent of the caregivers were categorised as compliant&#46; The factor with the greatest impact on treatment compliance was the tendency among caregivers to stop administering the drug if patients experienced adverse events&#46; The forgetfulness rate was low when patients were treated with rivastigmine patches&#46; Results from the adherence questionnaire are shown in <a class="elsevierStyleCrossRef" href="#fig0020">Fig&#46; 4</a>&#46;</p><elsevierMultimedia ident="fig0020"></elsevierMultimedia></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Discussion</span><p id="par0065" class="elsevierStylePara elsevierViewall">The characteristics of the caregivers assessed in this study coincide with those found by another recent study in our region that examined carers of patients treated with AChEI&#46;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> Most were women about 60 years of age&#44; with a primary education and actively employed&#46; Roughly 80&#37; shared a household with their patients and spent a mean of 10<span class="elsevierStyleHsp" style=""></span>hours daily caring for them&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">Generally speaking&#44; caregivers expressed satisfaction with transdermal treatment and considered that instructions were easy to follow and patches were easy to apply&#46; Concurring with these results&#44; a recent randomised study<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> found that 93&#37; of patients &#40;or their caregivers&#41; who had been receiving high doses of oral rivastigmine and who switched directly to high transdermal doses found the patches easy or very easy to use&#59; 95&#46;4&#37; found the treatment schedule easy or very easy to follow&#46; In our case&#44; ease of use as perceived by caregivers was also consistent with ease of use reported by doctors&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">Most of the caregivers expressed satisfaction with transdermal treatment&#44; as was the case in the randomised study mentioned above&#46;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> In that study&#44; 90&#46;7&#37; of patients&#47;caregivers who switched from high-dose oral rivastigmine to a transdermal form were satisfied with the patches&#59; in contrast&#44; 79&#46;1&#37; of patients who continued with oral treatment were satisfied &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>&#46;0001&#41;&#46; In our study&#44; doctors expressed a higher degree of overall satisfaction than carers &#40;92&#46;9&#37; vs&#46; 76&#46;5&#37;&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;0001&#41;&#46; This discrepancy may be explained by a number of factors&#46; On the one hand&#44; the question used to evaluate overall satisfaction differed between these groups&#44; and each had different possible responses&#46; On the other hand&#44; the factors that determine satisfaction with treatment probably differ between caregivers and health professionals&#46; For caregivers&#44; satisfaction tends to depend on whether the treatment is user friendly and how it affects activities of daily life&#46;<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7&#44;11&#44;17</span></a> It is quite unlikely that a health professional would rate these considerations as more important than treatment efficacy or safety on a satisfaction questionnaire&#46; Caregivers were not optimistic that their patients would be able to self-administer their patches but we should point out that if AD patients were able to do so&#44; it would decrease the burden on their caregivers&#46; This could be a decisive factor for satisfaction in this group&#44; considering that a large percentage of the carers in this study were actively employed&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">The study showed that CGI-C scores reported by both doctors and informal caregivers of AD patients are similar&#46; When these scores are compared to objective measuring instruments&#44; however&#44; we see that caregivers tend to overestimate neurological decline in their patients&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> In this study&#44; most caregivers reported improvement among patients after switching from oral to transdermal rivastigmine&#44; and they were significantly more likely to do so than doctors &#40;61&#46;4&#37; vs&#46; 53&#46;1&#37;&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;0001&#41;&#46; Nevertheless&#44; no objective measurements of patient decline were performed that would enable us to assess these perceptions&#44; nor did we evaluate the correlation between their opinion and the doctors&#8217; opinion&#46; In contrast&#44; some of the caregivers did not perceive any differences in the status of the patient with respect to the previous treatment&#46; Caregivers are not always conscious of the fact that efficacy of an AD treatment often manifests as stabilisation of the patient&#39;s state&#46;<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> This lack of improvement perceived by some caregivers in our study may affect their level of satisfaction with the patch&#46; It suggests that clear communication between doctor and caregiver is needed in order to create realistic expectations for the treatment&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">Patients treated with oral AChEI generally display low persistence&#46; A retrospective<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> study estimated that only 30&#46;8&#37; of patients remained in treatment with AChEI 6 months after having started&#59; use of low doses was cited as a risk factor for stopping treatment&#46; In our case&#44; persistence with transdermal rivastigmine reported at the 6-month mark was 87&#46;3&#37;&#46; This considerably higher figure may be partially due to the fact that all patients received high doses of rivastigmine&#46; Nevertheless&#44; the inherent advantages of the transdermal route are also likely to have had a strong impact&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">The most frequent reason for stopping treatment was local skin reaction&#46; Although these are the most frequent reactions caused by treatment with transdermal drugs&#44; they tend to be mild to moderate in the case of rivastigmine patches&#46;<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">21&#44;22</span></a> Cutaneous reactions can be lessened by changing patches daily&#44; and almost all caregivers in the study complied with this guideline&#46; In addition&#44; simple patient care routines&#44; such as removing the patch carefully and using emollients and topical corticosteroids&#44; decrease the impact of skin reactions&#46;<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> In addition&#44; there were few cases of stopping transdermal treatment due to gastrointestinal disorders or other adverse effects&#44; which confirms the good tolerability of this route&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">Despite the high percentage of treatment permanence&#44; we observed only moderate treatment compliance &#40;57&#37;&#41;&#46; We did not record compliance for the patients&#8217; previous period of oral treatment&#46; Based on published evidence&#44; however&#44; it would be reasonable to think that compliance with transdermal treatment would be higher&#44; or at least that causes of poor compliance would be more easily avoidable than in oral treatment&#46; In an earlier prospective observational study in patients with poor adherence to oral treatment&#44;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> researchers found that treatment compliance increased as patients switched from oral to transdermal treatment&#46; When the percentage of patch users was at 64&#46;8&#37;&#44; treatment compliance had reached 73&#46;6&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> This figure is higher than that obtained by our study&#46; In part&#44; the difference could be due to the way compliance was assessed&#46; In the prospective study&#44; patients were considered compliant if they forgot &#60;20&#37; of their doses and took their medication as prescribed &#62;80&#37; of the time&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">Researchers have observed that patients taking tablets were more likely to forget their dose than patients using patches&#46;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> This study shows a low rate of forgotten doses&#59; in fact&#44; most of the caregivers classified as non-compliant made a conscious decision not to adhere to treatment&#46; More than a third temporarily suspended the patches when patients experienced adverse events&#46; The same cause of treatment non-compliance has been reported among patients taking oral medications for chronic illnesses that resemble AD in that treatment benefits are not immediately apparent&#46;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> This may indicate that caregivers for patients with AD will require additional training about the long-term benefits of treatment so that patients&#8217; experience with the transdermal route will yield optimal results&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">In conclusion&#44; most informal caregivers preferred transdermal rivastigmine to oral rivastigmine&#46; Caregivers reported few incidents of forgetting doses and they indicated that the patch was easy to use and apply with little impact on the carer&#39;s daily routine&#46; Most caregivers expressed satisfaction with transdermal treatment&#44; and like the doctors&#44; they perceived overall improvement in patients who had switched from the previous treatment&#46; Studies report positive user experience results&#44; acceptance of the transdermal form&#44; and acceptable tolerability of the rivastigmine patch at high doses &#40;9&#46;5<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#41; in patients with AD who had previously been treated with high oral doses &#40;9&#8211;12<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#41;&#46; One implication of these data is that it may be beneficial to market rivastigmine patches with higher doses &#40;13&#46;3<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#41;&#44; as has been confirmed by more recent randomised trials&#46;<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Funding</span><p id="par0110" class="elsevierStylePara elsevierViewall">This study received financial support from <span class="elsevierStyleGrantSponsor" id="gs0005">Novartis Farmac&#233;utica&#44; S&#46;A</span>&#46;</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Conflicts of interest</span><p id="par0115" class="elsevierStylePara elsevierViewall">Javier Ricart and Basilio Hern&#225;ndez are employed by Novartis Farmac&#233;utica&#44; SA&#46; Ram&#243;n Re&#241;&#233; has no conflicts of interest to declare with regard to this study&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:11 [
        0 => array:2 [
          "identificador" => "xres318939"
          "titulo" => array:5 [
            0 => "Abstract"
            1 => "Introduction"
            2 => "Methods"
            3 => "Results"
            4 => "Conclusions"
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec301739"
          "titulo" => "Keywords"
        ]
        2 => array:2 [
          "identificador" => "xres318938"
          "titulo" => array:5 [
            0 => "Resumen"
            1 => "Introducci&#243;n"
            2 => "M&#233;todos"
            3 => "Resultados"
            4 => "Conclusiones"
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec301740"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Patients and methods"
        ]
        6 => array:3 [
          "identificador" => "sec0015"
          "titulo" => "Results"
          "secciones" => array:5 [
            0 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Population characteristics"
            ]
            1 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "User experience"
            ]
            2 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Treatment satisfaction and preferences"
            ]
            3 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "CGI-C scale"
            ]
            4 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Compliance"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0045"
          "titulo" => "Discussion"
        ]
        8 => array:2 [
          "identificador" => "sec0050"
          "titulo" => "Funding"
        ]
        9 => array:2 [
          "identificador" => "sec0055"
          "titulo" => "Conflicts of interest"
        ]
        10 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2012-10-01"
    "fechaAceptado" => "2013-02-19"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec301739"
          "palabras" => array:7 [
            0 => "Alzheimer disease"
            1 => "Informal caregiver"
            2 => "Rivastigmine"
            3 => "Satisfaction"
            4 => "Clinical Global Impression of Change"
            5 => "Treatment compliance"
            6 => "Transdermal patch"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec301740"
          "palabras" => array:7 [
            0 => "Enfermedad de Alzheimer"
            1 => "Cuidador informal"
            2 => "Rivastigmina"
            3 => "Satisfacci&#243;n"
            4 => "Impresi&#243;n Cl&#237;nica Global de Cambio"
            5 => "Cumplimiento terap&#233;utico"
            6 => "Parche transd&#233;rmico"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span class="elsevierStyleSectionTitle" id="sect0010">Introduction</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Rivastigmine&#44; a treatment for mild to moderate Alzheimer disease &#40;AD&#41;&#44; is the first cholinesterase inhibitor to be available in the transdermal format&#46; We aim to describe user experience and satisfaction with the rivastigmine patch&#44; as well as any clinical changes perceived in patients&#46;</p> <span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Observational&#44; cross-sectional&#44; multicentre study with 239 investigators and 1851 informal caregivers of patients with mild to moderate AD&#46; Patients were treated with transdermal rivastigmine patches for &#8805;6 months and had previously received high doses of oral rivastigmine&#46;</p> <span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Mean caregiver age was 59&#46;8<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>14&#46;4<span class="elsevierStyleHsp" style=""></span>years and 70&#46;9&#37; were women&#46; They spent 10&#46;0<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>7&#46;1<span class="elsevierStyleHsp" style=""></span>hours per day providing care and 79&#46;8&#37; lived with the patient&#46; Patch instructions were described as easy to follow by 97&#46;1&#37; of the caregivers and 92&#46;1&#37; of them rated patch application as easy or very easy&#46; The most commonly cited disadvantage was adhesion problems &#40;26&#46;8&#37;&#41;&#46; Discontinuation of treatment was due to cutaneous reactions in most cases&#46; Overall&#44; 76&#46;5&#37; of the caregivers were satisfied or very satisfied with transdermal treatment and 77&#46;4&#37; considered that its interference with daily activities was minimal or null&#46; The patch was preferred to oral treatment by 94&#46;3&#37; of caregivers&#46; Clinical Global Impression of Change ratings improved according to 61&#46;3&#37; of the caregivers and 53&#37; of the investigators&#46; Few caregivers reported medication forgetfulness&#46;</p> <span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Most caregivers of patients with mild to moderate AD preferred the transdermal format of rivastigmine to the oral format&#46; Caregivers also reported overall satisfaction&#44; ease of use&#44; and reduced impact on daily activities for transdermal rivastigmine format&#44; in addition to patient improvement compared to their condition under the previous treatment&#46;</p>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span class="elsevierStyleSectionTitle" id="sect0035">Introducci&#243;n</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Rivastigmina&#44; tratamiento para la enfermedad de Alzheimer &#40;EA&#41; leve-moderada&#44; es el primer inhibidor de la colinesterasa administrable por v&#237;a transd&#233;rmica&#46; Se describen la experiencia de uso y la satisfacci&#243;n de los cuidadores informales con los parches de rivastigmina&#44; as&#237; como el cambio cl&#237;nico percibido en los pacientes con su empleo&#46;</p> <span class="elsevierStyleSectionTitle" id="sect0040">M&#233;todos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Estudio observacional&#44; transversal y multic&#233;ntrico&#44; con 239 investigadores y 1851 cuidadores informales de pacientes con EA leve-moderada&#44; tratados con rivastigmina transd&#233;rmica durante &#8805;6 meses&#44; y que previamente recib&#237;an dosis altas de rivastigmina por v&#237;a oral&#46;</p> <span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">La edad media de los cuidadores fue 59&#44;8<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>14&#44;4 a&#241;os &#40;70&#44;9&#37; mujeres&#41;&#46; El 79&#44;8&#37; compart&#237;a domicilio con el paciente&#44; dedicando 10&#44;0<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>7&#44;1<span class="elsevierStyleHsp" style=""></span>h&#47;d&#237;a a su cuidado&#46; Para la mayor&#237;a de los cuidadores las instrucciones del parche fueron comprensibles &#40;97&#44;1&#37;&#41; y la aplicaci&#243;n f&#225;cil o muy f&#225;cil &#40;92&#44;1&#37;&#41;&#46; La principal dificultad mencionada fueron problemas de adhesi&#243;n &#40;26&#44;8&#37;&#41;&#46; En general&#44; los abandonos del tratamiento se produjeron por reacciones cut&#225;neas&#46; El 76&#44;5&#37; de los cuidadores estuvieron satisfechos o muy satisfechos con el parche y el 77&#44;4&#37; consider&#243; que interfer&#237;a poco o nada en las actividades diarias propias&#46; El 94&#44;3&#37; prefiri&#243; la v&#237;a transd&#233;rmica respecto a la v&#237;a oral&#46; La Impresi&#243;n Cl&#237;nica Global de Cambio fue mejor en alg&#250;n grado para el 61&#44;3&#37; de los cuidadores y para el 53&#37; de los investigadores&#46; Se notificaron pocos olvidos de la medicaci&#243;n&#46;</p> <span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">La mayor&#237;a de los cuidadores de pacientes con EA leve-moderada prefirieron la v&#237;a transd&#233;rmica de rivastigmina a la v&#237;a oral&#44; notificando satisfacci&#243;n global&#44; facilidad de uso e impacto reducido en sus actividades diarias propias con la ruta transd&#233;rmica&#44; as&#237; como mejora de los pacientes respecto al tratamiento anterior&#46;</p>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Please cite this article as&#58; Re&#241;&#233; R&#44; Ricart J&#44; Hern&#225;ndez B&#44; en representaci&#243;n de los investigadores del Estudio Experience&#46; Experiencia de uso y satisfacci&#243;n con rivastigmina transd&#233;rmica en cuidadores de pacientes con enfermedad de Alzheimer de leve a moderada previamente tratados con rivastigmina oral a dosis altas&#46; Neurolog&#237;a&#46; 2014&#59;29&#58;86&#8211;93&#46;</p>"
      ]
    ]
    "multimedia" => array:7 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2279
            "Ancho" => 2821
            "Tamanyo" => 349480
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Detailed reasons most frequently cited by caregivers of AD patients for not starting transdermal rivastigmine treatment &#40;A&#41; and for suspending transdermal rivastigmine treatment &#40;B&#41;&#46; Items 10 and 11 on the doctors&#8217; ad hoc questionnaire reporting on user experience&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1340
            "Ancho" => 2799
            "Tamanyo" => 264981
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Caregivers&#8217; and researchers&#8217; overall satisfaction with the current treatment &#40;rivastigmine patch&#41; for patients with AD&#46; Items 7 and 5 from the respective ad hoc questionnaires&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig0015"
        "etiqueta" => "Figure 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 1014
            "Ancho" => 2392
            "Tamanyo" => 122496
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Clinical Global Impressions-Change &#40;CGI-C&#41; rating for patient status&#44; provided by caregivers and doctors to compare patient health under current and previous treatments&#46;</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "fig0020"
        "etiqueta" => "Figure 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 1392
            "Ancho" => 3426
            "Tamanyo" => 270018
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Caregiver compliance with transdermal rivastigmine treatment&#46; Adapted Morisky adherence scale&#46;</p>"
        ]
      ]
      4 => array:7 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">SD&#58; standard deviation&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Total carers <span class="elsevierStyleItalic">N</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>1851&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Carer characteristics</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Age &#40;years&#41;&#44; mean</span><span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">SD</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">59&#46;8<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>14&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Sex &#40;female&#41;&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1313 &#40;70&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Educational level&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Primary education&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">807 &#40;43&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Secondary education&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">508 &#40;27&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Higher education&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">263 &#40;14&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>No studies&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">252 &#40;13&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Employment status&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Retired&#47;Ineligible&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1173 &#40;63&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Employed&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">628 &#40;33&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Unemployed&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50 &#40;2&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Sharing household with patient &#40;yes&#41;&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1478 &#40;79&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Care description</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Time spent as patient&#39;s carer &#40;years&#44; mean</span><span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">SD&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;4<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>2&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Time spent performing care tasks per day &#40;hours&#44; mean</span><span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">SD&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&#46;0<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>7&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Number of medications administered daily</span><span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">SD</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#46;0<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>4&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Time spent daily preparing and administering all of the patient&#39;s medications &#40;hours&#44; mean</span><span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">SD&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;8<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>1&#46;59&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab465340.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Includes all daily doses of the patient&#39;s medications &#40;tablets&#44; inhalers&#44; patches&#44; etc&#46;&#41;&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Sociodemographic data from informal caregivers in the study&#59; description of the care they provide to their patients&#46;</p>"
        ]
      ]
      5 => array:7 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Carers&#8217; experience&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Total carers<span class="elsevierStyleItalic">N</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>1851&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Responsible for applying the patch &#40;carer&#41;&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1697 &#40;91&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Clarity of the instructions for patch use&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">&#8216;</span>Quite clear&#8217; or &#8216;clear&#8217;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1797 &#40;97&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">&#8216;</span>Somewhat unclear&#8217; or &#8216;completely unclear&#8217;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&#46;4 &#40;2&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Ease in applying the patch&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8216;Very easy&#8217; or &#8216;easy&#8217;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1705 &#40;92&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8216;Intermediate&#8217;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">137 &#40;7&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8216;Difficult&#8217; or &#8216;very difficult&#8217;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;0&#46;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Main reasons for difficulty&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>The patch comes loose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20 &#40;26&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Difficulty rotating patches to different locations&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14 &#40;15&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Difficulty opening the envelope&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;14&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Difficulties specific to individual carers<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;8&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Poor patient cooperation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;8&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Dermatitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;7&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Presence of hair in the application area&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;3&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Whether the patch met initial expectations</span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8216;Much better&#8217; or &#8216;somewhat better&#8217;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1173 &#40;63&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8216;Neither better nor worse&#8217;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">598 &#40;32&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8216;Significantly worse&#8217; or &#8216;much worse&#8217;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">80 &#40;4&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab465341.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Mild parkinsonism&#44; illiteracy&#44; other&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Carers&#8217; experience with using high-dose transdermal rivastigmine as treatment for Alzheimer disease&#46;</p>"
        ]
      ]
      6 => array:7 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">All items show the mean percentage &#40;standard deviation&#41; except where otherwise stated&#46;</p><p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">AD&#58; Alzheimer disease&#59; AChEI&#58; acetylcholinesterase inhibitors&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Doctors&#8217; experience&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Total doctors<span class="elsevierStyleItalic">N</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>278&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Patients diagnosed with AD divided by total patients seen in the clinic</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27&#46;9 &#40;20&#46;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Treated with AChEI<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">81&#46;1 &#40;16&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Treated with rivastigmine<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&#46;5 &#40;19&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Treated transdermally<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">67&#46;7 &#40;22&#46;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Previously treated with oral rivastigmine<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">42&#46;2 &#40;21&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Prior treatment with high-dose oral rivastigmine &#40;9&#8211;12<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#41;<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">61&#46;2 &#40;27&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Percentage of the total patients treated with transdermal rivastigmine who remain on that treatment after 3 months</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">90&#46;5 &#40;10&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Percentage of the total patients treated with transdermal rivastigmine who remain on that treatment after 6 months</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">87&#46;3 &#40;11&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Patients previously treated with oral rivastigmine who prefer the transdermal form</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">87&#46;7 &#40;12&#46;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Doctors who report the transdermal form as being easier to use than the oral form&#44; based on their patients&#8217; opinions&#44; n &#40;&#37;&#41;</span><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">228 &#40;90&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab465339.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Percentage calculated with respect to the previous item&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0020"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Percentage calculated with respect to the total responses obtained&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Doctors&#8217; experience with high-dose transdermal rivastigmine as treatment for Alzheimer disease based on results in their clinics&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:26 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EFNS guidelines for the diagnosis and management of Alzheimer&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Hort"
                            1 => "J&#46;T&#46; O&#8217;Brien"
                            2 => "G&#46; Gainotti"
                            3 => "T&#46; Pirttila"
                            4 => "B&#46;O&#46; Popescu"
                            5 => "I&#46; Rektorova"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1468-1331.2010.03040.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Neurol"
                        "fecha" => "2010"
                        "volumen" => "17"
                        "paginaInicial" => "1236"
                        "paginaFinal" => "1248"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20831773"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cholinesterase inhibitors for Alzheimer&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "J&#46; Birks"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Cochrane Database Syst Rev"
                        "fecha" => "2006"
                        "volumen" => "25"
                        "paginaInicial" => "CD005593"
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673611604388"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46;W&#46; Jann"
                            1 => "K&#46;L&#46; Shirley"
                            2 => "G&#46;W&#46; Small"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2165/00003088-200241100-00003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Pharmacokinet"
                        "fecha" => "2002"
                        "volumen" => "41"
                        "paginaInicial" => "719"
                        "paginaFinal" => "739"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12162759"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "B&#46;P&#46; Imbimbo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "CNS Drugs"
                        "fecha" => "2001"
                        "volumen" => "15"
                        "paginaInicial" => "375"
                        "paginaFinal" => "390"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11475943"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0020729208001550"
                          "estado" => "S300"
                          "issn" => "00207292"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A rivastigmine patch for the treatment of Alzheimer&#39;s disease and Parkinson&#39;s disease dementia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "J&#46; Cummings"
                            1 => "B&#46; Winblad"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1586/14737175.7.11.1457"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Rev Neurother"
                        "fecha" => "2007"
                        "volumen" => "7"
                        "paginaInicial" => "1457"
                        "paginaFinal" => "1463"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17997695"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer&#39;s disease&#58; a review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46; Kurz"
                            1 => "M&#46; Farlow"
                            2 => "G&#46; Lef&#232;vre"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1742-1241.2009.02052.x"
                      "Revista" => array:7 [
                        "tituloSerie" => "Int J Clin Pract"
                        "fecha" => "2009"
                        "volumen" => "63"
                        "paginaInicial" => "799"
                        "paginaFinal" => "805"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19392927"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673611607010"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A six-month double-blind&#44; randomized&#44; placebo-controlled study of a transdermal patch in Alzheimer&#39;s disease &#8211; rivastigmine patch versus capsule"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46; Winblad"
                            1 => "J&#46; Cummings"
                            2 => "N&#46; Andreasen"
                            3 => "G&#46; Grossberg"
                            4 => "M&#46; Onofrj"
                            5 => "C&#46; Sadowsky"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/gps.1788"
                      "Revista" => array:7 [
                        "tituloSerie" => "Int J Geriatr Psychiatry"
                        "fecha" => "2007"
                        "volumen" => "22"
                        "paginaInicial" => "456"
                        "paginaFinal" => "467"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17380489"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673610611890"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety and tolerability of the rivastigmine patch&#58; results of a 28-week open-label extension"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Grossberg"
                            1 => "C&#46; Sadowsky"
                            2 => "H&#46; Fr&#246;stl"
                            3 => "L&#46; Fr&#246;lich"
                            4 => "J&#46; Nagel"
                            5 => "S&#46; Tekin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Alzheimer Dis Assoc Disord"
                        "fecha" => "2009"
                        "volumen" => "23"
                        "paginaInicial" => "158"
                        "paginaFinal" => "164"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19484917"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Caregiver burden in Alzheimer&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "P&#46;W&#46; Slattum"
                            1 => "M&#46;A&#46; Johnson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Consult Pharm"
                        "fecha" => "2004"
                        "volumen" => "19"
                        "paginaInicial" => "352"
                        "paginaFinal" => "362"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16553479"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "R&#46; Blesa"
                            1 => "C&#46; Ballard"
                            2 => "J&#46;M&#46; Orgogozo"
                            3 => "R&#46; Lane"
                            4 => "S&#46;K&#46; Thomas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1212/01.wnl.0000302372.08983.38"
                      "Revista" => array:6 [
                        "tituloSerie" => "Neurology"
                        "fecha" => "2007"
                        "volumen" => "69"
                        "paginaInicial" => "S23"
                        "paginaFinal" => "S28"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18071154"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46; Winblad"
                            1 => "A&#46;K&#46; Kawata"
                            2 => "K&#46;M&#46; Beusterien"
                            3 => "S&#46;K&#46; Thomas"
                            4 => "A&#46; Wimo"
                            5 => "R&#46; Lane"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/gps.1806"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Geriatr Psychiatry"
                        "fecha" => "2007"
                        "volumen" => "22"
                        "paginaInicial" => "485"
                        "paginaFinal" => "491"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17407176"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Evaluaci&#243;n de la conveniencia del cambio de v&#237;a de administraci&#243;n de rivastigmina en pacientes con enfermedad de Alzheimer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Blesa Gonz&#225;lez"
                            1 => "M&#46; Boada Rovira"
                            2 => "C&#46; Mart&#237;nez Parra"
                            3 => "D&#46; Gil-Saladi&#233;"
                            4 => "C&#46;A&#46; Almagro"
                            5 => "A&#46;L&#46; Gobartt V&#225;zquez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.nrl.2010.10.007"
                      "Revista" => array:6 [
                        "tituloSerie" => "Neurolog&#237;a"
                        "fecha" => "2011"
                        "volumen" => "26"
                        "paginaInicial" => "262"
                        "paginaFinal" => "271"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21227548"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Donepezil&#44; galantamine&#44; rivastigmine and memantine for the treatment of Alzheimer&#39;s disease &#40;review of NICE technology appraisal guidance 111&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "NICE technology appraisal guidance 217"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:2 [
                        "fecha" => "2011"
                        "editorial" => "National Institute for Health and Clinical Excellence"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:1 [
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:2 [
                        "titulo" => "ECDEU assessment manual for psychopharmacology"
                        "serieFecha" => "1976"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Concurrent and predictive validity of a self-reported measure of medication adherent"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "D&#46;E&#46; Morisky"
                            1 => "L&#46;W&#46; Green"
                            2 => "D&#46;M&#46; Lewvine"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Medical Care"
                        "fecha" => "1986"
                        "volumen" => "24"
                        "paginaInicial" => "67"
                        "paginaFinal" => "74"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3945130"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Perfil del cuidador informal asociado al manejo cl&#237;nico del paciente con enfermedad de Alzheimer no respondedor al tratamiento sintom&#225;tico de la enfermedad"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "J&#46;L&#46; Molinuevo"
                            1 => "B&#46; Hern&#225;ndez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.nrl.2011.05.011"
                      "Revista" => array:7 [
                        "tituloSerie" => "Neurolog&#237;a"
                        "fecha" => "2011"
                        "volumen" => "26"
                        "paginaInicial" => "518"
                        "paginaFinal" => "527"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21803459"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673604166816"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Donepecilo bucodispersable&#58; &#191;est&#225;n los cuidadores principales del paciente con enfermedad de Alzheimer m&#225;s satisfechos que con la formulaci&#243;n tradicional de donepecilo&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "C&#46; Sevilla"
                            1 => "P&#46;E&#46; Jim&#233;nez-Caballero"
                            2 => "V&#46; Alfonso"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Neurol"
                        "fecha" => "2009"
                        "volumen" => "49"
                        "paginaInicial" => "451"
                        "paginaFinal" => "457"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19859884"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Differences between physician and caregiver evaluations in Alzheimer&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "E&#46; Sinforiani"
                            1 => "C&#46; Pasotti"
                            2 => "L&#46; Chiapella"
                            3 => "P&#46; Malinverni"
                            4 => "C&#46; Zucchella"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Funct Neurol"
                        "fecha" => "2010"
                        "volumen" => "25"
                        "paginaInicial" => "205"
                        "paginaFinal" => "209"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21388581"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cholinesterase inhibitors stabilize Alzheimer&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "E&#46; Giacobini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann N Y Acad Sci"
                        "fecha" => "2000"
                        "volumen" => "920"
                        "paginaInicial" => "321"
                        "paginaFinal" => "327"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11193171"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands&#58; a retrospective cohort study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46; Kr&#246;ger"
                            1 => "R&#46; van Marum"
                            2 => "P&#46; Souverein"
                            3 => "T&#46; Egberts"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2165/11538230-000000000-00000"
                      "Revista" => array:6 [
                        "tituloSerie" => "Drugs Aging"
                        "fecha" => "2010"
                        "volumen" => "27"
                        "paginaInicial" => "663"
                        "paginaFinal" => "675"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20658794"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Skin tolerability associated with transdermal drug delivery systems&#58; an overview"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "I&#46; Ale"
                            1 => "J&#46;M&#46; Lachapelle"
                            2 => "H&#46;I&#46; Maibach"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s12325-009-0075-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Adv Ther"
                        "fecha" => "2009"
                        "volumen" => "26"
                        "paginaInicial" => "920"
                        "paginaFinal" => "935"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19967501"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rivastigmine transdermal patch skin tolerability&#58; results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "J&#46;L&#46; Cummings"
                            1 => "M&#46;R&#46; Farlow"
                            2 => "X&#46; Meng"
                            3 => "S&#46; Tekin"
                            4 => "J&#46;T&#46; Olin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Drug Invest"
                        "fecha" => "2010"
                        "volumen" => "30"
                        "paginaInicial" => "41"
                        "paginaFinal" => "49"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Transdermal rivastigmine&#58; management of cutaneous adverse events and review of the literature"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46; Greenspon"
                            1 => "N&#46; Herrmann"
                            2 => "D&#46;N&#46; Adam"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2165/11592230-000000000-00000"
                      "Revista" => array:6 [
                        "tituloSerie" => "CNS Drugs"
                        "fecha" => "2011"
                        "volumen" => "25"
                        "paginaInicial" => "575"
                        "paginaFinal" => "583"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21623641"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Evaluaci&#243;n de las estrategias para mejorar el cumplimiento terap&#233;utico en la pr&#225;ctica cl&#237;nica habitual en pacientes incumplidores con demencia tipo Alzheimer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "J&#46;L&#46; Molinuevo"
                            1 => "F&#46;J&#46; Arranz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Neurol"
                        "fecha" => "2012"
                        "volumen" => "54"
                        "paginaInicial" => "65"
                        "paginaFinal" => "73"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22234564"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A review of compliance to treatment in Alzheimer&#39;s disease&#58; potential benefits of a transdermal patch"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "G&#46; Small"
                            1 => "B&#46; Dubois"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Curr Res Med Opin"
                        "fecha" => "2007"
                        "volumen" => "23"
                        "paginaInicial" => "2705"
                        "paginaFinal" => "2713"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Randomized&#44; double-blind&#44; parallel-group&#44; 48-week study for efficacy and safety of a higher-dose rivastigmine patch &#40;15 vs&#46; 10<span class="elsevierStyleHsp" style=""></span>cm<span class="elsevierStyleSup">2</span>&#41; in Alzheimer&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Cummings"
                            1 => "L&#46; Froelich"
                            2 => "S&#46;E&#46; Black"
                            3 => "S&#46; Bakchine"
                            4 => "G&#46; Bellelli"
                            5 => "J&#46;L&#46; Molinuevo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000340056"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dement Geriatr Cogn Disord"
                        "fecha" => "2012"
                        "volumen" => "33"
                        "paginaInicial" => "341"
                        "paginaFinal" => "353"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22796905"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/21735808/0000002900000002/v1_201403090041/S217358081300182X/v1_201403090041/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "17109"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "CO1"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/21735808/0000002900000002/v1_201403090041/S217358081300182X/v1_201403090041/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217358081300182X?idApp=UINPBA00004N"
]

Article information

ISSN: 21735808
Original language: English

DOI:10.1016/j.nrleng.2013.12.004

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	5	1	6
2024 October	27	8	35
2024 September	28	9	37
2024 August	48	7	55
2024 July	29	4	33
2024 June	51	7	58
2024 May	25	9	34
2024 April	58	14	72
2024 March	67	13	80
2024 February	71	20	91
2024 January	55	7	62
2023 December	72	15	87
2023 November	55	9	64
2023 October	53	13	66
2023 September	22	5	27
2023 August	26	14	40
2023 July	13	11	24
2023 June	28	9	37
2023 May	57	4	61
2023 April	40	4	44
2023 March	37	13	50
2023 February	17	5	22
2023 January	9	11	20
2022 December	31	8	39
2022 November	25	8	33
2022 October	30	12	42
2022 September	52	7	59
2022 August	47	25	72
2022 July	21	5	26
2022 June	23	11	34
2022 May	21	15	36
2022 April	31	13	44
2022 March	32	7	39
2022 February	28	15	43
2022 January	15	7	22
2021 December	20	18	38
2021 November	38	12	50
2021 October	23	10	33
2021 September	17	16	33
2021 August	19	7	26
2021 July	14	9	23
2021 June	19	8	27
2021 May	18	7	25
2021 April	30	10	40
2021 March	36	10	46
2021 February	12	3	15
2021 January	13	9	22
2020 December	21	12	33
2020 November	14	9	23
2020 October	16	10	26
2020 September	15	11	26
2020 August	17	11	28
2020 July	20	12	32
2020 June	15	6	21
2020 May	23	18	41
2020 April	14	5	19
2020 March	25	3	28
2020 February	13	4	17
2020 January	14	6	20
2019 December	32	7	39
2019 November	11	3	14
2019 October	18	5	23
2019 September	17	1	18
2019 August	11	3	14
2019 July	20	16	36
2019 June	40	13	53
2019 May	99	9	108
2019 April	67	4	71
2019 March	11	4	15
2019 February	17	7	24
2019 January	8	5	13
2018 December	11	2	13
2018 November	18	10	28
2018 October	28	7	35
2018 September	29	10	39
2018 August	11	4	15
2018 July	4	9	13
2018 June	9	6	15
2018 May	13	3	16
2018 April	17	9	26
2018 March	7	4	11
2018 February	5	1	6
2018 January	11	4	15
2017 December	11	1	12
2017 November	15	5	20
2017 October	11	4	15
2017 September	10	5	15
2017 August	17	9	26
2017 July	13	1	14
2017 June	49	10	59
2017 May	26	2	28
2017 April	6	3	9
2017 March	10	26	36
2017 February	13	2	15
2017 January	13	2	15
2016 December	17	9	26
2016 November	22	5	27
2016 October	24	11	35
2016 September	31	7	38
2016 August	31	5	36
2016 July	23	7	30
2016 June	28	10	38
2016 May	17	18	35
2016 April	24	14	38
2016 March	29	20	49
2016 February	21	8	29
2016 January	12	2	14
2015 December	14	5	19
2015 November	25	5	30
2015 October	23	8	31
2015 September	31	9	40
2015 August	17	5	22
2015 July	19	13	32
2015 June	12	13	25
2015 May	23	13	36
2015 April	30	17	47
2015 March	30	13	43
2015 February	32	6	38
2015 January	37	8	45
2014 December	65	8	73
2014 November	37	5	42
2014 October	47	11	58
2014 September	58	10	68
2014 August	39	9	48
2014 July	36	17	53
2014 June	34	12	46
2014 May	31	13	44
2014 April	33	20	53
2014 March	33	22	55

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter